Similarly, Ho et al. identified a clear EFS and OS benefit for alloHSCT vs. consolidation chemotherapy in patients identified as having high-risk FLT3-ITD-mutated AML and in patients with low-risk FLT3-ITD-mutated AML and WT NPM1 who received alloHCT in first remission; in patients with low-risk FLT3-ITD-mutated AML and NPM1 mutation a benefit from alloHSCT was not evident in terms of EFS and OS [53]. This evidence concerns the gene FLT3 and acute myeloid leukemia.